Clinical Trial Update: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation [Phase 3]

View source ↗

Summary

Phase III study comparing almonertinib to platinum-based chemotherapy as first-line therapy in locally advanced or metastatic non-small cell lung cancer with un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN